Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Cutting Edge: Clonally Restricted Production of the Neurotrophins Brain-Derived Neurotrophic Factor and Neurotrophin-3 mRNA by Human Immune Cells and Th1/Th2-Polarized Expression of Their Receptors

Michal Besser and Rudolf Wank
J Immunol June 1, 1999, 162 (11) 6303-6306;
Michal Besser
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rudolf Wank
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  •   FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Expression of trkB gp95 on PBMC. a, FACS analysis of unstimulated lymphocytes. PBL were stained with anti-trkB gp95 polyclonal rabbit Ab and CD4 Ab. Twelve percent of the Th cells carried the receptor. b, Expression of trkB gp95 mRNA in CD4-positive (+) and CD4-depleted (−) PBMC. Cells were either unstimulated or stimulated with the following: PHA (1%).or anti-CD3 (20 μg) in combination with 20 U/ml IL-2 or 100 U/ml IL-4. Only unstimulated CD4+ cells expressed the receptor mRNA, whereas after stimulation CD4+ as well as CD4− cells were positive for trkB gp95 mRNA. PC*, positive control (cDNA of neuroblastoma cell line SMS-KCN); NC§, negative control (no cDNA added). The constitutively expressed GAPDH served as a PCR and gel-loading control.

  •   FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Amplification of trkB, trkC, and NT-3 mRNA in various cell lines and clones by RT-PCR. trkB gp95 mRNA (a),trkB gp145 mRNA (b), trkC mRNA (c), and NT-3 mRNA (d) expression in B-LCL, the monocyte cell line MM1, the γδ− clone EM-17, and CD4+ T cell clones 200, 234, 305, 401, 403, 407, 411, and 425. The CD4+ clones 305 and 401 were also stimulated with anti-CD3 (20 μg) and 20 U/ml IL-2 for 3 days. The constitutively expressed GAPDH served as a PCR and gel-loading control.

  •   FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Influence of different cytokines on trkB gp145 expression. trkB gp145 mRNA was amplified by RT-PCR. Th0 clone 234, Th2 clone 305, and PBMC were treated with IL-2 (20 U/ml), IL-4 (100 U/ml), BDNF (100 ng/ml), NT-4 (100 ng/ml), IFN-γ (500 U/ml), or with medium alone (-) for 24 h. PC*, positive control (cDNA of the neuroblastoma cell line SMS-KCN was added), NC§, negative control (cDNA of PC-12 cells, not expressing the trkB mRNA, was added). The constitutively expressed GAPDH served as a PCR and gel-loading control.

  •   FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Phenotyping of CD4+ Th clones according to their secretion of IL-4 and IFN-γ determined by ELISA of cell culture supernatants after 24 h. a, IFN-γ production as measured in nanograms per ml. b, IL-4 production in pg/ml. Data represent the mean ± SEM of eight experiments. c, Clones producing mainly IL-4 were assigned a Th2 phenotype; clones producing mainly IFN-γ as Th1 and clones secreting both cytokines in higher amounts were assigned a Th0 phenotype.

  •   FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Effect of irradiation on BDNF secretion. BDNF levels in pg/ml were determined by ELISA for three untreated and 20-Gy-irradiated B-LCL (A.N., B.E., R.E.), the monocyte cell line MM1, and four Th clones (234, 305, 401, 411). The cell culture supernatants were collected 3 days after irradiation. Data represent the mean ± SEM of three experiments.

PreviousNext
Back to top

In this issue

The Journal of Immunology: 162 (11)
The Journal of Immunology
Vol. 162, Issue 11
1 Jun 1999
  • Table of Contents
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cutting Edge: Clonally Restricted Production of the Neurotrophins Brain-Derived Neurotrophic Factor and Neurotrophin-3 mRNA by Human Immune Cells and Th1/Th2-Polarized Expression of Their Receptors
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cutting Edge: Clonally Restricted Production of the Neurotrophins Brain-Derived Neurotrophic Factor and Neurotrophin-3 mRNA by Human Immune Cells and Th1/Th2-Polarized Expression of Their Receptors
Michal Besser, Rudolf Wank
The Journal of Immunology June 1, 1999, 162 (11) 6303-6306;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cutting Edge: Clonally Restricted Production of the Neurotrophins Brain-Derived Neurotrophic Factor and Neurotrophin-3 mRNA by Human Immune Cells and Th1/Th2-Polarized Expression of Their Receptors
Michal Besser, Rudolf Wank
The Journal of Immunology June 1, 1999, 162 (11) 6303-6306;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Cutting Edge: T Cell Responses to B.1.1.529 (Omicron) SARS-CoV-2 Variant Induced by COVID-19 Infection and/or mRNA Vaccination Are Largely Preserved
  • Cutting Edge: SARS-CoV-2 Infection Induces Robust Germinal Center Activity in the Human Tonsil
  • Cutting Edge: Enhanced Antitumor Immunity in ST8Sia6 Knockout Mice
Show more CUTTING EDGE

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606